Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. [electronic resource]
Producer: 20150120Description: 1942-51 p. digitalISSN:- 1474-547X
- Adenine -- analogs & derivatives
- Adult
- Anti-HIV Agents -- therapeutic use
- CD4 Lymphocyte Count
- Cholesterol, HDL -- metabolism
- Cholesterol, LDL -- metabolism
- Darunavir
- Deoxycytidine -- analogs & derivatives
- Drug Resistance, Viral
- Drug Therapy, Combination
- Emtricitabine
- Female
- HIV Infections -- drug therapy
- HIV-1
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Organophosphonates -- therapeutic use
- Pyrrolidinones -- therapeutic use
- Raltegravir Potassium
- Ritonavir -- therapeutic use
- Sulfonamides -- therapeutic use
- Tenofovir
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.